Literature DB >> 1315227

IL-6 in malignant pleural effusions and its augmentation by intrapleural instillation of IL-2.

H Yanagawa1, S Sone, M Munekata, S Atagi, A Nii, T Ogura.   

Abstract

The levels and activities of endogenous IL-6 in malignant pleural effusions due to lung cancer before and during daily intrapleural instillations of recombinant IL-2 were examined by enzyme immunoassay and bioassay using an IL-6-dependent murine hybridoma cell line MH60.BSF2. Before therapy, malignant pleural effusions contained various levels of IL-6. Daily intrapleural instillation of recombinant IL-2 for treatment of malignant pleurisy resulted in significant augmentation of the levels and activities of IL-6 in the pleural effusions. On fractionation of the pleural effusion by chromatography, one major peak of material with a mol. wt of 24 kD showed IL-6 activity. In contrast, no significant level of tumour necrosis factor-alpha or IL-1 beta was detectable in pleural effusions before or during local IL-2 therapy. These data suggest that IL-2 is an important regulatory factor of secondary IL-6 production.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1315227      PMCID： PMC1554304          DOI： 10.1111/j.1365-2249.1992.tb03063.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


  32 in total

1.  B cell growth and differentiation induced by supernatants of transformed epithelial cell lines.

Authors:  F C Rawle; J Shields; S H Smith; V Iliescu; M Merkenschlager; P C Beverley; R E Callard
Journal:  Eur J Immunol       Date:  1986-08       Impact factor: 5.532

Review 2.  Immunotherapy of cancer using interleukin 2: current status and future prospects.

Authors:  S A Rosenberg
Journal:  Immunol Today       Date:  1988-02

3.  Human glioblastoma cells release interleukin 6 in vivo and in vitro.

Authors:  E Van Meir; Y Sawamura; A C Diserens; M F Hamou; N de Tribolet
Journal:  Cancer Res       Date:  1990-10-15       Impact factor: 12.701

4.  Regulation of interleukin-6 expression in cultured human blood monocytes and monocyte-derived macrophages.

Authors:  J Bauer; U Ganter; T Geiger; U Jacobshagen; T Hirano; T Matsuda; T Kishimoto; T Andus; G Acs; W Gerok
Journal:  Blood       Date:  1988-10       Impact factor: 22.113

5.  Establishment of an interleukin 6 (IL 6)/B cell stimulatory factor 2-dependent cell line and preparation of anti-IL 6 monoclonal antibodies.

Authors:  T Matsuda; T Hirano; T Kishimoto
Journal:  Eur J Immunol       Date:  1988-06       Impact factor: 5.532

6.  Regulation of BSF-2/IL-6 production by human mononuclear cells. Macrophage-dependent synthesis of BSF-2/IL-6 by T cells.

Authors:  Y Horii; A Muraguchi; S Suematsu; T Matsuda; K Yoshizaki; T Hirano; T Kishimoto
Journal:  J Immunol       Date:  1988-09-01       Impact factor: 5.422

7.  Synthesis and secretion of multiple forms of beta 2-interferon/B-cell differentiation factor 2/hepatocyte-stimulating factor by human fibroblasts and monocytes.

Authors:  L T May; J Ghrayeb; U Santhanam; S B Tatter; Z Sthoeger; D C Helfgott; N Chiorazzi; G Grieninger; P B Sehgal
Journal:  J Biol Chem       Date:  1988-06-05       Impact factor: 5.157

8.  Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas.

Authors:  M Kawano; T Hirano; T Matsuda; T Taga; Y Horii; K Iwato; H Asaoku; B Tang; O Tanabe; H Tanaka
Journal:  Nature       Date:  1988-03-03       Impact factor: 49.962

9.  B cell stimulatory factor-2 is involved in the differentiation of cytotoxic T lymphocytes.

Authors:  Y Takai; G G Wong; S C Clark; S J Burakoff; S H Herrmann
Journal:  J Immunol       Date:  1988-01-15       Impact factor: 5.422

10.  Antitumor activity of recombinant interleukin 6 in mice.

Authors:  J J Mulé; J K McIntosh; D M Jablons; S A Rosenberg
Journal:  J Exp Med       Date:  1990-03-01       Impact factor: 14.307
View more
  6 in total

1.  Tumor-associated lymphocytes (TAL) are competent to produce higher levels of cytokines in neoplastic pleural and peritoneal effusions than those found in sera and are able to release into culture higher levels of IL-2 and IL-6 than those released by PBMC.

Authors:  G Mantovani; A Macciò; R Versace; M Pisano; P Lai; S Esu; M Ghiani; D Dessì; E Turnu; M C Santona
Journal:  J Mol Med (Berl)       Date:  1995-08       Impact factor: 4.599

2.  [Association of genetic polymorphisms in IL-6 and IL-1β gene with risk of lung cancer in female non-smokers].

Authors:  Meng Su; Baosen Zhou
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2014-08-20

3.  Serum levels of interleukin 6 in patients with lung cancer.

Authors:  H Yanagawa; S Sone; Y Takahashi; T Haku; S Yano; T Shinohara; T Ogura
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

4.  Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.

Authors:  Xiaohong Tan; Julian Carretero; Zhao Chen; Jishuai Zhang; Yanxiao Wang; Jicheng Chen; Xiubin Li; Hui Ye; Chuanhao Tang; Xuan Cheng; Ning Hou; Xiao Yang; Kwok-Kin Wong
Journal:  PLoS One       Date:  2013-11-15       Impact factor: 3.240

5.  Autonomous expressions of cytokine genes by human lung cancer cells and their paracrine regulation.

Authors:  K Mizuno; S Sone; E Orino; A Nii; T Ogura
Journal:  Jpn J Cancer Res       Date:  1994-02

6.  Secretome of pleural effusions associated with non-small cell lung cancer (NSCLC) and malignant mesothelioma: therapeutic implications.

Authors:  Albert D Donnenberg; James D Luketich; Vera S Donnenberg
Journal:  Oncotarget       Date:  2019-11-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.